Visual Outcomes Of The Rayone Emv Enhanced Monofocal Intraocular Lens Implant.

The enhanced monofocal non-diffractive RayOne EMV intraocular lens (IOL) is designed to induce positive spherical aberration across a controlled aspheric surface and provide superior intermediate vision when compared with standard monofocals. This retrospective case series was performed to assess the real-world visual outcomes of the RayOne EMV IOL for both emmetropic and mini-monovision target refractions.

Single centre, multiple surgeon, private practice, London, UK. 

Eyes implanted with the RayOne EMV IOL during cataract surgery or refractive lens exchange were identified between 16/07/2020 and 21/02/2022. After exclusion of eyes with visually significant ocular co-morbidities, three groups were analysed: 1) all individual eyes with emmetropic target (n=90); 2) bilateral eyes with emmetropic target (n=56); and 3) bilateral eyes with mini-monovision target (n=30). Post-operative visual acuity, refraction and quality of vision were assessed at 2 weeks.

90 eyes implanted with EMV lens targeting emmetropia achieved mean uncorrected distance visual acuity (UDVA) of 0.00 ±0.12 LogMAR, and uncorrected near visual acuity (UNVA) of 0.46 ±0.19 LogMAR. 56 eyes implanted with bilateral EMV lens targeting emmetropia achieved mean binocular UDVA of -0.03 ±0.10 and binocular UNVA of 0.33 ±0.11 LogMAR. 30 eyes implanted with bilateral EMV lens with mini-monovision target (range -0.5 to -1.4 Diopters in non-dominant eye) achieved mean binocular UDVA of -0.01 ±0.20 and binocular UNVA of 0.22 ±0.12 LogMAR. 

Implantation of the RayOne EMV IOL achieves excellent outcomes for both uncorrected distance and intermediate vision. In the setting of mini-monovision, superior near vision was achieved with 100% patients reading N6 or better. There were no reports of photic phenomena highlighting the advantage of this non-diffractive optic design for achieving optimal spectacle independence with low risk of dysphotopsia.